Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Laymon

Showing results (31-40 of 90) with videos related to

Pageof 9
Sort By:
Molecular Imaging and Biology|March 3, 2011
Human biodistribution and dosimetry of the PET radioligand [¹¹C]flumazenil (FMZ)Charles M Laymon, Rajesh Narendran, Neale S Mason, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2009
Human biodistribution and dosimetry of the D2/3 agonist 11C-N-propylnorapomorphine (11C-NPA) determined from PETCharles M Laymon, N Scott Mason, W Gordon Frankle, et al.
ACS Omega|March 9, 2026
[<sup>64</sup>Cu]Cu-Labeled αCD11b Diabody as a Novel PET Tracer for the Detection of Immunosuppression in GlioblastomaBo Li, Sydney A Jackson, Amelia Stepniak, et al.
Frontiers in Integrative Neuroscience|September 30, 2022
Physical activity, memory function, and hippocampal volume in adults with Down syndromeJamie C Peven, Benjamin L Handen, Charles M Laymon, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 28, 2010
A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatumRajesh Narendran, N Scott Mason, Charles M Laymon, et al.
Neuroimage|January 4, 2011
Inter-rater reliability of manual and automated region-of-interest delineation for PiB PETBedda L Rosario, Lisa A Weissfeld, Charles M Laymon, et al.
Neuroimage. Clinical|December 8, 2015
Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjectsJames M Mountz, Charles M Laymon, Ann D Cohen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 6, 2015
Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PETYin J Chen, Bedda L Rosario, Wenzhu Mowrey, et al.
Synapse (New York, N.Y.)|March 21, 2009
Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studiesRajesh Narendran, W Gordon Frankle, N Scott Mason, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|September 30, 2020
Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndromeSigan L Hartley, Benjamin L Handen, Darlynne Devenny, et al.
Pageof 9

Showing results (31-40 of 90) with videos related to

Sort By:
Pageof 9
Molecular Imaging and Biology|March 3, 2011
Human biodistribution and dosimetry of the PET radioligand [¹¹C]flumazenil (FMZ)Charles M Laymon, Rajesh Narendran, Neale S Mason, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2009
Human biodistribution and dosimetry of the D2/3 agonist 11C-N-propylnorapomorphine (11C-NPA) determined from PETCharles M Laymon, N Scott Mason, W Gordon Frankle, et al.
ACS Omega|March 9, 2026
[<sup>64</sup>Cu]Cu-Labeled αCD11b Diabody as a Novel PET Tracer for the Detection of Immunosuppression in GlioblastomaBo Li, Sydney A Jackson, Amelia Stepniak, et al.
Frontiers in Integrative Neuroscience|September 30, 2022
Physical activity, memory function, and hippocampal volume in adults with Down syndromeJamie C Peven, Benjamin L Handen, Charles M Laymon, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 28, 2010
A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatumRajesh Narendran, N Scott Mason, Charles M Laymon, et al.
Neuroimage|January 4, 2011
Inter-rater reliability of manual and automated region-of-interest delineation for PiB PETBedda L Rosario, Lisa A Weissfeld, Charles M Laymon, et al.
Neuroimage. Clinical|December 8, 2015
Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjectsJames M Mountz, Charles M Laymon, Ann D Cohen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 6, 2015
Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PETYin J Chen, Bedda L Rosario, Wenzhu Mowrey, et al.
Synapse (New York, N.Y.)|March 21, 2009
Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studiesRajesh Narendran, W Gordon Frankle, N Scott Mason, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|September 30, 2020
Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndromeSigan L Hartley, Benjamin L Handen, Darlynne Devenny, et al.
Pageof 9